Details for Patent: 9,173,881

Which drugs does patent 9,173,881 protect, and when does it expire?

Patent 9,173,881 protects UPTRAVI and is included in two NDAs.

Protection for UPTRAVI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in twenty-eight countries.

Summary for Patent: 9,173,881

Title:	Therapeutic compositions containing macitentan
Abstract:	The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Martine Clozel
Assignee:	Actelion Pharmaceuticals Ltd
Application Number:	US14/335,657
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 9,173,881

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes	9,173,881*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-010	May 23, 2026		RX	Yes	No	9,173,881*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-011	May 23, 2026		RX	Yes	No	9,173,881*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-001	Dec 21, 2015	AB	RX	Yes	No	9,173,881*PED				Y

Foreign Priority and PCT Information for Patent: 9,173,881

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/IB2008/053252	Aug 13, 2008

International Family Members for US Patent 9,173,881

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	073031
Australia	2009280843
Brazil	PI0917661
Canada	2731370